Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniela E. Kirwan is active.

Publication


Featured researches published by Daniela E. Kirwan.


American Journal of Tropical Medicine and Hygiene | 2012

Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?

Daniela E. Kirwan; María Kathia Cárdenas; Robert H. Gilman

In 2011 the World Health Organization approved Xpert MTB/RIF for tuberculosis diagnosis and recommended its rapid implementation. Xpert MTB/RIF is accurate: sensitivity is 72.5 -98.2% (smear-negative and -positive cases, respectively) and specificity 99.2%. Benefits include same-day diagnosis and simultaneous detection of rifampicin resistance. However, the test has some shortcomings and has not had time for thorough evaluation. Cost-effectiveness studies are difficult to perform and few have been completed. Existing data suggest cost-effectiveness in some, but not all, settings. The urgent need for better diagnostics is evident. Yet, serial implementation of new technologies causes ineffective spending and fragmentation of services. How new tests are incorporated into existing diagnostic algorithms affects both outcomes and costs. More detailed data on performance, effect on patient-important outcomes, and costs when used with adjunct tests are needed for each setting before implementation. While awaiting further clarification it seems prudent to slow its implementation among resource-constrained tuberculosis control programs.


Science Translational Medicine | 2017

Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity

Luisa Paris; Ruben Magni; Fatima Zaidi; Robyn P. Araujo; Neal Saini; Michael Harpole; Jorge Coronel; Daniela E. Kirwan; Hannah Steinberg; Robert H. Gilman; Emanuel F. Petricoin; Roberto Nisini; Alessandra Luchini; Lance A. Liotta

The Mycobacterium tuberculosis–specific antigen lipoarabinomannan measured in the urine of HIV-negative, pulmonary TB-infected patients correlates with disease severity. Tuberculosis is no longer on the LAM Lipoarabinomannan (LAM) is a component of the cell wall shed by Mycobacterium tuberculosis, the bacteria responsible for tuberculosis, an infection mainly affecting the lungs. LAM can be detected in urine samples from patients coinfected with HIV, but current LAM detection methods have failed for HIV-negative patients. Using hydrogel “nanocage” nanoparticles and a chemical bait with high affinity for LAM, Paris et al. showed that patients negative for HIV with active tuberculosis infections had detectably higher concentrations of LAM in their urine than patients without active tuberculosis infections. Nanocages could also be used to detect cytokines and other antigens present in low concentrations in urine, demonstrating the versatility of the technology as a method to detect and monitor infections. An accurate urine test for pulmonary tuberculosis (TB), affecting 9.6 million patients worldwide, is critically needed for surveillance and treatment management. Past attempts failed to reliably detect the mycobacterial glycan antigen lipoarabinomannan (LAM), a marker of active TB, in HIV-negative, pulmonary TB–infected patients’ urine (85% of 9.6 million patients). We apply a copper complex dye within a hydrogel nanocage that captures LAM with very high affinity, displacing interfering urine proteins. The technology was applied to study pretreatment urine from 48 Peruvian patients, all negative for HIV, with microbiologically confirmed active pulmonary TB. LAM was quantitatively measured in the urine with a sensitivity of >95% and a specificity of >80% (n = 101) in a concentration range of 14 to 2000 picograms per milliliter, as compared to non-TB, healthy and diseased, age-matched controls (evaluated by receiver operating characteristic analysis; area under the curve, 0.95; 95% confidence interval, 0.9005 to 0.9957). Urinary LAM was elevated in patients with a higher mycobacterial burden (n = 42), a higher proportion of weight loss (n = 37), or cough (n = 50). The technology can be configured in a variety of formats to detect a panel of previously undetectable very-low-abundance TB urinary analytes. Eight of nine patients who were smear-negative and culture-positive for TB tested positive for urinary LAM. This technology has broad implications for pulmonary TB screening, transmission control, and treatment management for HIV-negative patients.


Microbial Drug Resistance | 2012

A New Approach for Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis

Mirko Zimic; Sebastian Loli; Robert H. Gilman; Andres H. Gutiérrez; Patricia Fuentes; Milagros Cotrina; Daniela E. Kirwan; Patricia Sheen

BACKGROUND Pyrazinamide (PZA) is an important drug in the treatment of tuberculosis. Microbiological methods of PZA susceptibility testing are controversial and have low reproducibility. After conversion of PZA into pyrazinoic acid (POA) by the bacterial pyrazinamidase enzyme, the drug is expelled from the bacteria by an efflux pump. OBJECTIVE To evaluate the rate of POA extrusion from Mycobacterium tuberculosis as a parameter to detect PZA resistance. METHODS The rate of POA extrusion and PZA susceptibility determined by BACTEC 460 were measured for 34 strains in a previous study. PZA resistance was modeled in a logistic regression with the pyrazinoic efflux rate. RESULT POA efflux rate predicted PZA resistance with 70.83%-92.85% sensitivity and 100% specificity compared with BACTEC 460. CONCLUSION POA efflux rate could be a useful tool for predicting PZA resistance in M. tuberculosis. Further exploration of this approach may lead to the development of new tools for diagnosing PZA resistance, which may be of public health importance.


Tropical Medicine & International Health | 2009

The social reality of migrant men with tuberculosis in Kathmandu: implications for DOT in practice.

Daniela E. Kirwan; Brian D. Nicholson; Sushil C Baral; James Newell

Objective  To establish which of the many possible linkages between tuberculosis (TB), direct observation of treatment (DOTS), and the social reality of migrant workers in Kathmandu are the most relevant to the health outcomes and economic and social well‐being of these populations, and which are amenable to possible interventions and high‐yield policy changes.


Clinical Infectious Diseases | 2017

Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.

Alvaro Proaño; Marjory A. Bravard; José W. López; Gwenyth Lee; David P. Bui; Sumona Datta; Germán Comina; Mirko Zimic; Jorge Coronel; Luz Caviedes; José L. Cabrera; Antonio Salas; Eduardo Ticona; Nancy M. Vu; Daniela E. Kirwan; Maria Cristina I. Loader; Jon S. Friedland; David Moore; Carlton A. Evans; Brian H. Tracey; Robert H. Gilman

Summary This is the first research to evaluate cough frequency continuously over 24-hour periods and to characterize associations with mycobacterial load and treatment. This study provides novel information on the circadian cycle of cough frequency and risk factors for increased cough frequency.


Journal of Clinical Microbiology | 2016

Microscopic Observation Drug Susceptibility Assay for Rapid Diagnosis of Lymph Node Tuberculosis and Detection of Drug Resistance

Daniela E. Kirwan; Cesar Ugarte-Gil; Robert H. Gilman; Luz Caviedes; Hasan Rizvi; Eduardo Ticona; Gonzalo Chávez; José L. Cabrera; Eduardo D. Matos; Carlton A. Evans; David Moore; Jon S. Friedland

ABSTRACT In this study, 132 patients with lymphadenopathy were investigated. Fifty-two (39.4%) were diagnosed with tuberculosis (TB). The microscopic observation drug susceptibility (MODS) assay provided rapid (13 days), accurate diagnosis (sensitivity, 65.4%) and reliable drug susceptibility testing (DST). Despite its lower sensitivity than that of other methods, its faster results and simultaneous DST are advantageous in resource-poor settings, supporting the incorporation of MODS into diagnostic algorithms for extrapulmonary TB.


BMJ Open | 2016

Protocol for studying cough frequency in people with pulmonary tuberculosis

Alvaro Proaño; Marjory A. Bravard; Brian H. Tracey; José W. López; Germán Comina; Mirko Zimic; Jorge Coronel; Gwenyth Lee; Luz Caviedes; José L. Cabrera; Antonio Salas; Eduardo Ticona; Daniela E. Kirwan; Jon S. Friedland; Carlton A. Evans; David Moore; Robert H. Gilman

Introduction Cough is a key symptom of tuberculosis (TB) as well as the main cause of transmission. However, a recent literature review found that cough frequency (number of coughs per hour) in patients with TB has only been studied once, in 1969. The main aim of this study is to describe cough frequency patterns before and after the start of TB treatment and to determine baseline factors that affect cough frequency in these patients. Secondarily, we will evaluate the correlation between cough frequency and TB microbiological resolution. Methods This study will select participants with culture confirmed TB from 2 tertiary hospitals in Lima, Peru. We estimated that a sample size of 107 patients was sufficient to detect clinically significant changes in cough frequency. Participants will initially be evaluated through questionnaires, radiology, microscopic observation drug susceptibility broth TB-culture, auramine smear microscopy and cough recordings. This cohort will be followed for the initial 60 days of anti-TB treatment, and throughout the study several microbiological samples as well as 24 h recordings will be collected. We will describe the variability of cough episodes and determine its association with baseline laboratory parameters of pulmonary TB. In addition, we will analyse the reduction of cough frequency in predicting TB cure, adjusted for potential confounders. Ethics and dissemination Ethical approval has been obtained from the ethics committees at each participating hospital in Lima, Peru, Asociación Benéfica PRISMA in Lima, Peru, the Universidad Peruana Cayetano Heredia in Lima, Peru and Johns Hopkins University in Baltimore, USA. We aim to publish and disseminate our findings in peer-reviewed journals. We also expect to create and maintain an online repository for TB cough sounds as well as the statistical analysis employed.


American Journal of Tropical Medicine and Hygiene | 2014

Congenital Transmission of Multidrug-Resistant Tuberculosis

Nora Espiritu; Lino Aguirre; Oswaldo Jave; Luis Sanchez; Daniela E. Kirwan; Robert H. Gilman

This article presents a case of multidrug-resistant tuberculosis (TB) in a Peruvian infant. His mother was diagnosed with disseminated TB, and treatment commenced 11 days postpartum. The infant was diagnosed with TB after 40 days and died at 2 months and 2 days of age. Congenital transmission of TB to the infant was suspected, because direct postpartum transmission was considered unlikely; also, thorough screening of contacts for TB was negative. Spoligotyping confirmed that both mother and baby were infected with identical strains of the Beijing family (SIT1).


American Journal of Respiratory and Critical Care Medicine | 2018

Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis

Katharine Fox; Daniela E. Kirwan; Ashley M. Whittington; Nitya Krishnan; Brian D. Robertson; Robert H. Gilman; José W. López; Shivani Singh; Joanna C. Porter; Jon S. Friedland

&NA; Rationale: Platelets may interact with the immune system in tuberculosis (TB) to regulate human inflammatory responses that lead to morbidity and spread of infection. Objectives: To identify a functional role of platelets in the innate inflammatory and matrix‐degrading response in TB. Methods: Markers of platelet activation were examined in plasma from 50 patients with TB before treatment and 50 control subjects. Twenty‐five patients were followed longitudinally. Platelet‐monocyte interactions were studied in a coculture model infected with live, virulent Mycobacterium tuberculosis (M.tb) and dissected using qRT‐PCR, Luminex multiplex arrays, matrix degradation assays, and colony counts. Immunohistochemistry detected CD41 (cluster of differentiation 41) expression in a pulmonary TB murine model, and secreted platelet factors were measured in BAL fluid from 15 patients with TB and matched control subjects. Measurements and Main Results: Five of six platelet‐associated mediators were upregulated in plasma of patients with TB compared with control subjects, with concentrations returning to baseline by Day 60 of treatment. Gene expression of the monocyte collagenase MMP‐1 (matrix metalloproteinase‐1) was upregulated by platelets in M.tb infection. Platelets also enhanced M.tb‐induced MMP‐1 and ‐10 secretion, which drove type I collagen degradation. Platelets increased monocyte IL‐1 and IL‐10 and decreased IL‐12 and MDC (monocyte‐derived chemokine; also known as CCL‐22) secretion, as consistent with an M2 monocyte phenotype. Monocyte killing of intracellular M.tb was decreased. In the lung, platelets were detected in a TB mouse model, and secreted platelet mediators were upregulated in human BAL fluid and correlated with MMP and IL‐1&bgr; concentrations. Conclusions: Platelets drive a proinflammatory, tissue‐degrading phenotype in TB.


American Journal of Tropical Medicine and Hygiene | 2016

Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection

Matthew Z. Dudley; Patricia Sheen; Robert H. Gilman; Eduardo Ticona; Jon S. Friedland; Daniela E. Kirwan; Luz Caviedes; Richard Rodriguez; Lilia Cabrera; Jorge Coronel; Louis Grandjean; David Moore; Carlton A. Evans; Luz Huaroto; Víctor Chávez-Pérez; Mirko Zimic

Hospital infection control measures are crucial to tuberculosis (TB) control strategies within settings caring for human immunodeficiency virus (HIV)–positive patients, as these patients are at heightened risk of developing TB. Pyrazinamide (PZA) is a potent drug that effectively sterilizes persistent Mycobacterium tuberculosis bacilli. However, PZA resistance associated with mutations in the nicotinamidase/pyrazinamidase coding gene, pncA, is increasing. A total of 794 patient isolates obtained from four sites in Lima, Peru, underwent spoligotyping and drug resistance testing. In one of these sites, the HIV unit of Hospital Dos de Mayo (HDM), an isolation ward for HIV/TB coinfected patients opened during the study as an infection control intervention: circulating genotypes and drug resistance pre- and postintervention were compared. All other sites cared for HIV-negative outpatients: genotypes and drug resistance rates from these sites were compared with those from HDM. HDM patients showed high concordance between multidrug resistance, PZA resistance according to the Wayne method, the two most common genotypes (spoligotype international type [SIT] 42 of the Latino American-Mediterranean (LAM)-9 clade and SIT 53 of the T1 clade), and the two most common pncA mutations (G145A and A403C). These associations were absent among community isolates. The infection control intervention was associated with 58–92% reductions in TB caused by SIT 42 or SIT 53 genotypes (odds ratio [OR] = 0.420, P = 0.003); multidrug-resistant TB (OR = 0.349, P < 0.001); and PZA-resistant TB (OR = 0.076, P < 0.001). In conclusion, pncA mutation typing, with resistance testing and spoligotyping, was useful in identifying a nosocomial TB outbreak and demonstrating its resolution after implementation of infection control measures.

Collaboration


Dive into the Daniela E. Kirwan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlton A. Evans

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar

Jorge Coronel

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar

Mirko Zimic

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar

José W. López

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar

Luz Caviedes

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar

Alvaro Proaño

Cayetano Heredia University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge